NO20100268L - Anvendelse av gjaercellevegger til behandling og/eller forebygging av hyperinsulinemi - Google Patents

Anvendelse av gjaercellevegger til behandling og/eller forebygging av hyperinsulinemi

Info

Publication number
NO20100268L
NO20100268L NO20100268A NO20100268A NO20100268L NO 20100268 L NO20100268 L NO 20100268L NO 20100268 A NO20100268 A NO 20100268A NO 20100268 A NO20100268 A NO 20100268A NO 20100268 L NO20100268 L NO 20100268L
Authority
NO
Norway
Prior art keywords
yeast cell
cell walls
treat
prevent hyperinsulinemia
hyperinsulinemia
Prior art date
Application number
NO20100268A
Other languages
English (en)
Other versions
NO342072B1 (no
Inventor
Martine Laville
Julie-Anne Nazare
Eric Oriol
Original Assignee
Lesaffre & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lesaffre & Cie filed Critical Lesaffre & Cie
Publication of NO20100268L publication Critical patent/NO20100268L/no
Publication of NO342072B1 publication Critical patent/NO342072B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Oppfinnelsen angår anvendelse av gjærcellevegger til å fremstille en farmasøytisk sammensetning for å behandle og/eller forebygge hyperinsulinaemi.
NO20100268A 2007-07-25 2010-02-23 Anvendelse av gjærcellevegger til behandling og/eller forebygging av hyperinsulinemi NO342072B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0756731A FR2919187B1 (fr) 2007-07-25 2007-07-25 Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.
PCT/EP2008/059815 WO2009013357A1 (fr) 2007-07-25 2008-07-25 Utilisation d'écorces de levure pour le traitement et / ou la prévention de l'hyperinsulinémie

Publications (2)

Publication Number Publication Date
NO20100268L true NO20100268L (no) 2010-02-23
NO342072B1 NO342072B1 (no) 2018-03-19

Family

ID=39271450

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20100268A NO342072B1 (no) 2007-07-25 2010-02-23 Anvendelse av gjærcellevegger til behandling og/eller forebygging av hyperinsulinemi

Country Status (16)

Country Link
US (1) US9750762B2 (no)
EP (1) EP2170359B1 (no)
JP (1) JP5530354B2 (no)
KR (1) KR101593705B1 (no)
CN (1) CN101801400B (no)
AU (1) AU2008278975B2 (no)
CA (1) CA2696462C (no)
ES (1) ES2586244T3 (no)
FR (1) FR2919187B1 (no)
NO (1) NO342072B1 (no)
PL (1) PL2170359T3 (no)
RU (1) RU2463065C2 (no)
SG (1) SG169346A1 (no)
SI (1) SI2170359T1 (no)
WO (1) WO2009013357A1 (no)
ZA (1) ZA201000381B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949064B1 (fr) * 2009-08-14 2011-10-07 Lesaffre & Cie Nouvelles compositions destinees a la prevention et/ou au traitement du diabete
FR2978967B1 (fr) * 2011-08-09 2020-03-20 Lesaffre Et Compagnie Ecorces de levure enrichies en vitamine d2, compositions les contenant, leur procede de preparation, leurs utilisations et dispositif permettant la mise en oeuvre du procede
EP2870969A1 (fr) * 2013-11-08 2015-05-13 Biocodex Composition pharmaceutique pour la réduction de la masse adipeuse
CN107233298B (zh) * 2016-03-28 2021-01-22 复旦大学 一种促进蛋白多肽药物口服吸收的酵母细胞壁微粒制剂
EP3761995A1 (en) * 2018-03-08 2021-01-13 DSM IP Assets B.V. Yeast beta glucans
EP3685681A1 (en) 2019-01-23 2020-07-29 Lesaffre et Compagnie A yeast product, and a composition comprising it, for use as a prebiotic agent
WO2023175153A1 (en) 2022-03-18 2023-09-21 Fumi Ingredients B.V. A microbial cell extract, method for obtaining said microbial cell extract and use of said microbial cell extract

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61167622A (ja) * 1985-01-22 1986-07-29 Asahi Breweries Ltd 糖尿病コントロ−ル剤
JP2756907B2 (ja) * 1993-12-28 1998-05-25 日本製紙株式会社 酵母エキス組成物及びその製造法並びにそれを含有する飼料
FR2800076B1 (fr) * 1999-10-22 2003-11-14 Lesaffre & Cie Mannoproteines solubles
FR2825004B1 (fr) 2001-05-22 2005-02-11 Bio Springer Produit dietetique satiant
US7459159B2 (en) * 2003-08-11 2008-12-02 Lesaffre Et Compagnie Yeast cell walls for the treatment or prevention of hyperglycemia or for the stabilization of glycemia
UA85561C2 (ru) * 2003-08-11 2009-02-10 Лезаффр Э Компани Применение клеточных стенок дрожжей для лечения или профилактики гипергликемии или для стабилизации содержания сахара в крови
JP4302684B2 (ja) * 2005-06-30 2009-07-29 株式会社 ミヤトウ野草研究所 コタラヒンブツ葉エキスを含有した健康食品の製造方法

Also Published As

Publication number Publication date
RU2010104981A (ru) 2011-08-27
ES2586244T3 (es) 2016-10-13
US9750762B2 (en) 2017-09-05
KR101593705B1 (ko) 2016-02-12
ZA201000381B (en) 2010-10-27
FR2919187B1 (fr) 2009-11-27
KR20100063039A (ko) 2010-06-10
CA2696462C (fr) 2016-08-23
CN101801400B (zh) 2013-10-16
PL2170359T3 (pl) 2016-11-30
EP2170359A1 (fr) 2010-04-07
EP2170359B1 (fr) 2016-05-11
JP5530354B2 (ja) 2014-06-25
CA2696462A1 (fr) 2009-01-29
FR2919187A1 (fr) 2009-01-30
US20100196413A1 (en) 2010-08-05
SI2170359T1 (sl) 2016-10-28
WO2009013357A1 (fr) 2009-01-29
NO342072B1 (no) 2018-03-19
CN101801400A (zh) 2010-08-11
SG169346A1 (en) 2011-03-30
AU2008278975A1 (en) 2009-01-29
JP2010534223A (ja) 2010-11-04
AU2008278975B2 (en) 2013-09-19
RU2463065C2 (ru) 2012-10-10

Similar Documents

Publication Publication Date Title
NO20100268L (no) Anvendelse av gjaercellevegger til behandling og/eller forebygging av hyperinsulinemi
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
WO2010059004A3 (ko) 스네일-p53 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
NO20085031L (no) Benzimidazolmodulatorer av VR1
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
WO2009156484A3 (en) Organic compounds
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
NO20084850L (no) MGLUR5 modulatorer I
NO20083057L (no) Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
UA95310C2 (ru) Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20084749L (no) Organiske forbindelser og deres anvendelser
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees